We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Abbott Diagnostics- Hematology Division

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Blood Biomarker Predicts Dementia in Cerebral Small Vessel Disease

By LabMedica International staff writers
Posted on 24 Feb 2021
Print article
Image: The Simoa HD-1 Analyzer is a novel fully automated digital immunoassay analyzer with single-molecule sensitivity and multiplexing (Photo courtesy of Quanterix).
Image: The Simoa HD-1 Analyzer is a novel fully automated digital immunoassay analyzer with single-molecule sensitivity and multiplexing (Photo courtesy of Quanterix).
Cerebral small vessel disease (SVD) is a highly prevalent condition, which causes lacunar stroke, vascular cognitive impairment and vascular dementia. Few treatments have been shown to delay disease progression.

Neurofilament light chain (NfL) is a blood marker sensitive to neuroaxonal damage and increased levels occur in neurodegenerative diseases. In a cross-sectional study in SVD, NfL levels were associated with cognition and disability. However, if NfL is to be used to predict outcome, studies are required to demonstrate baseline NfL predicts future dementia risk.

An international team of scientists associated with the University of Cambridge (Cambridge, UK) enrolled a total of 121 patients with symptomatic SVD, defined as a clinical lacunar stroke syndrome with MRI evidence of an anatomically corresponding lacunar infarct, at least three months post stroke. Of the 121 subjects recruited, blood was available for 113, and in 90 patients blood samples were available from at least at two time points. Average baseline age was 70, and 74% of participants were men.

Serum Nfl analysis was the same for all samples using the same single-molecule array instrument, the Simoa HD-1 (Quanterix, Billerica, MA, USA). The team used the capture monoclonal antibody (mAB) 47:3 and the biotinylated detector mAB 2:1 (UmanDiagnostics, Umeå, Sweden), transferred onto the Simoa platform.

The team reported baseline serum NfL levels averaged 36.51 pg/mL. Cross-sectional analyses showed NfL levels were inversely associated with global cognitive function, executive function, and processing speed. They also were negatively correlated with disability. Higher NfL levels were positively associated with lacune count, cerebral microbleed count, white matter hyperintensities, and diffusion tensor imaging (DTI) measures, and were negatively associated with normalized brain volume.

Over five years, both global cognition and processing speed declined significantly. Higher NfL at baseline predicted lower function in global cognition independently of clinical markers and baseline cognition. A total of 107 participants had complete baseline DTI and NfL data; 19 of them converted to dementia over time. Higher baseline NfL predicted not only dementia, but changes in lacune count, microbleed count, and brain volume, independently of initial MRI baseline values and patient age.

The authors concluded that prospective cohort study demonstrates that baseline NfL values predict cognitive decline and dementia rate over a five years follow-up duration in patients with severe SVD. NfL may be a useful prognostic marker in this disease. However, in contrast to diffusion tensor imaging (DTI), change in NfL values was not detected over a three years follow-up period with annual sampling, suggesting NfL is unlikely to be a useful surrogate marker in a phase 2 clinical trial. The study was published on February 8, 2021 in the Journal of Neurology, Neurosurgery, and Psychiatry.

Related Links:
University of Cambridge
Quanterix
UmanDiagnostics


New
Gold Supplier
Proficiency Assessment Software
CellaVision Proficiency Software
New
Laboratory Management Software
HERA
New
Gold Supplier
Molecular Diagnostic System
Singuway 9600 Pro
New
Gold Supplier
SARS-CoV-2 Multiplex Real-Time RT-PCR Assay
GSD NovaPrime Plus SARS-CoV-2

Print article

Channels

Industry

view channel
Illustration

Thermo Fisher Launches World’s First Fully Integrated Digital PCR (dPCR) System

Thermo Fisher Scientific Inc. (Waltham, MA, USA) has launched the world’s first fully integrated digital PCR (dPCR) system designed to provide highly accurate and consistent results within 90 minutes.... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.